Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
SanBio Co ( (JP:4592) ) just unveiled an update.
SanBio has finalized the terms for a new stock option program, approving the issuance of 75,000 share acquisition rights tied to an equal number of common shares at an exercise price of 1,898 yen per share. All of the options will be granted to three employees, underscoring the company’s use of equity-based compensation to align key staff with shareholder interests and support talent retention during its growth phase in the competitive biotech market.
The most recent analyst rating on (JP:4592) stock is a Sell with a Yen1815.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.
More about SanBio Co
SanBio Co., Ltd., listed on the TSE Growth market under code 4592, operates in the biopharmaceutical sector, focusing on the research, development, and commercialization of regenerative and cell-based therapies. The company targets unmet medical needs with innovative treatments, positioning itself within Japan’s growing biotech and life sciences industry.
Average Trading Volume: 1,828,871
Technical Sentiment Signal: Hold
Current Market Cap: Yen150.8B
For an in-depth examination of 4592 stock, go to TipRanks’ Overview page.